Contextualizing the pathology in the essential tremor cerebellar cortex: a patholog-omics approach.
Cerebellum
Dystonia
Essential tremor
Parkinson’s disease
Spinocerebellar ataxia
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
12
03
2019
accepted:
08
07
2019
revised:
08
07
2019
pubmed:
19
7
2019
medline:
17
9
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Several morphological changes, centered in/around Purkinje cells (PCs), have been identified in the cerebellum of essential tremor (ET) patients. These changes have not been contextualized within a broader degenerative disease spectrum, limiting their interpretability. To address this, we compared the severity and patterning of degenerative changes within the cerebellar cortex in patients with ET, other neurodegenerative disorders of the cerebellum (spinocerebellar ataxias (SCAs), multiple system atrophy (MSA)], and other disorders that may involve the cerebellum [Parkinson's disease (PD), dystonia]. Using a postmortem series of 156 brains [50 ET, 23 SCA (6 SCA3; 17 SCA 1, 2 or 6), 15 MSA, 29 PD, 14 dystonia, 25 controls], we generated data on 37 quantitative morphologic metrics, which were grouped into 8 broad categories: (1) PC loss, (2) heterotopic PCs, (3) PC dendritic changes, (4) PC axonal changes (torpedoes), (5) PC axonal changes (other than torpedoes), (6) PC axonal changes (torpedo-associated), (7) basket cell axonal hypertrophy, (8) climbing fiber-PC synaptic changes. Our analyses used z scored raw data for each metric across all diagnoses (5772 total data items). Principal component analysis revealed that diagnostic groups were not uniform with respect to cerebellar pathology. Dystonia and PD each differed from controls in only 2/37 metrics, whereas ET differed in 21, SCA3 in 8, MSA in 19, and SCA1/2/6 in 26 metrics. Comparing ET with primary disorders of cerebellar degeneration (i.e., SCAs), we observed a spectrum of changes reflecting differences of degree, being generally mild in ET and SCA3 and more severe in SCA1/2/6. Comparative analyses across morphologic categories demonstrated differences in relative expression, defining distinctive patterns of changes in these groups. Thus, the degree of cerebellar degeneration in ET aligns it with a milder end in the spectrum of cerebellar degenerative disorders, and a somewhat distinctive signature of degenerative changes marks each of these disorders.
Identifiants
pubmed: 31317229
doi: 10.1007/s00401-019-02043-7
pii: 10.1007/s00401-019-02043-7
pmc: PMC7285399
mid: NIHMS1595102
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-876Subventions
Organisme : NINDS NIH HHS
ID : R01 NS088257
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS104423
Pays : United States
Références
J Neural Transm (Vienna). 2006 Jul;113(7):829-43
pubmed: 16362839
Cerebellum. 2017 Apr;16(2):577-594
pubmed: 27734238
Brain. 2013 Oct;136(Pt 10):3051-61
pubmed: 24030953
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S91-4
pubmed: 9330994
Cerebellum. 2012 Sep;11(3):749-60
pubmed: 22198871
Acta Neuropathol. 2012 Jul;124(1):1-21
pubmed: 22684686
Mov Disord. 1997 Mar;12(2):133-47
pubmed: 9087971
Mov Disord. 2013 Nov;28(13):1854-9
pubmed: 23925732
J Neuropathol Exp Neurol. 2019 Feb 1;78(2):113-122
pubmed: 30590599
Acta Neuropathol. 2013 Jun;125(6):879-89
pubmed: 23543187
Cerebellum. 2013 Aug;12(4):493-503
pubmed: 23389921
Acta Neuropathol. 2017 Jan;133(1):121-138
pubmed: 27704282
Brain. 2007 Dec;130(Pt 12):3297-307
pubmed: 18025031
Clin Neurophysiol. 2013 Jul;124(7):1269-76
pubmed: 23422326
Handb Clin Neurol. 2012;103:399-421
pubmed: 21827903
Mov Disord. 2009 Aug 15;24(11):1600-5
pubmed: 19526585
Brain. 2014 Dec;137(Pt 12):3142-8
pubmed: 25367027
Cerebellum. 2017 Apr;16(2):473-482
pubmed: 27726094
Cerebellum. 2011 Jun;10(2):245-53
pubmed: 21128038
Mov Disord. 2009 Oct 30;24(14):2033-41
pubmed: 19750493
Handb Clin Neurol. 2018;155:259-272
pubmed: 29891064
Brain. 2012 Jan;135(Pt 1):105-16
pubmed: 22120148
Eur J Neurol. 2012 Apr;19(4):625-30
pubmed: 22136494
Lancet Neurol. 2010 Jun;9(6):613-22
pubmed: 20451458
Neurology. 2006 Jun 13;66(11):1756-9
pubmed: 16769958
J Neurosci. 2016 May 11;36(19):5362-72
pubmed: 27170132
Acta Neuropathol. 2011 Sep;122(3):323-30
pubmed: 21638087
NPJ Parkinsons Dis. 2016 Dec 01;2:16025
pubmed: 28725705
Handb Clin Neurol. 2012;103:461-73
pubmed: 21827907
J Neurol Sci. 2018 Sep 15;392:105-112
pubmed: 30036781
Mov Disord. 2016 Mar;31(3):393-401
pubmed: 26861543
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S85-8
pubmed: 9330992
Acta Neuropathol. 2006 Oct;112(4):389-404
pubmed: 16906426
Folia Neuropathol. 2015;53(3):193-202
pubmed: 26443310
Neurobiol Dis. 2015 Oct;82:397-408
pubmed: 26253607
Cerebellum. 2018 Apr;17(2):104-110
pubmed: 28791574
Brain. 2014 Dec;137(Pt 12):3149-59
pubmed: 25273997
Neurodegener Dis. 2017;17(4-5):155-165
pubmed: 28463835
Exp Neurol. 2013 Mar;241:95-104
pubmed: 23195594
Alcohol Clin Exp Res. 2001 Feb;25(2):228-35
pubmed: 11236837
Arch Neurol. 2008 Jan;65(1):101-7
pubmed: 18195146
Clin Neurophysiol. 2018 Jan;129(1):282-283
pubmed: 29122444
Mov Disord. 2017 May;32(5):757-768
pubmed: 28186664
Cerebellum. 2014 Aug;13(4):433-9
pubmed: 24590661
Mov Disord. 2014 Nov;29(13):1637-47
pubmed: 24531928
J Neuropathol Exp Neurol. 2010 Mar;69(3):262-71
pubmed: 20142764
Handb Clin Neurol. 2012;103:423-36
pubmed: 21827904
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879